Stock listing

NASDAQ:AKTX Akari Therapeutics PLC Stock

Follow Akari Therapeutics PLC into a list and get an email when it puts out news.

Share price · NASDAQ:AKTX

$7.18 USD +0.53 (+8.0%)

Close on Nov 20, 2026

Past year -61.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$6.20 – $7.44 USDNov 20, 2026
Volume
15,265 sharesNov 20, 2026
Market cap
$16.41M USDAt the close on Nov 20, 2026 · price × 2.29M shares outstanding
52-week range
$3.02 – $29.32 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$546,691 USDMedian day 42,293 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Akari Therapeutics PLC logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:AKTX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$7.18+0.53+8.0%$7.00$7.44$6.2015,265
$6.65+0.95+16.7%$5.87$7.25$5.719,795
$5.70-0.81-12.4%$6.11$6.257$5.7011,457
$6.51-0.29-4.3%$7.045$7.045$6.3528,032
$6.80+0.29+4.5%$6.52$7.547$6.5221,412
$6.51-0.94-12.6%$7.67$7.69$6.5113,956
$7.45+0.32+4.5%$7.46$7.65$7.15622,353
$7.13-0.53-6.9%$7.46$7.58$6.9426,989
$7.66+0.29+3.9%$7.61$7.89$7.3341,712
$7.37-0.38-4.9%$7.77$8.375$7.2753,243
$7.75-1.54-16.6%$8.80$9.025$7.6031,878
$9.29+1.14+14.0%$8.13$9.38$8.1387,902
$8.15+0.31+4.0%$8.39$8.61$7.9963,279
$7.84-0.40-4.9%$8.40$8.40$7.5711,862
$8.24+0.24+3.0%$8.50$8.95$8.07145,653
$8.00-1.20-13.0%$9.13$9.83$8.0097,012
$9.20+0.62+7.2%$8.665$9.325$8.2942,293
$8.58+0.95+12.5%$7.94$8.64$7.9438,455
$7.63-0.595-7.2%$7.64$8.45$7.6367,835
$8.225+0.125+1.5%$8.00$8.45$7.8414,391
$8.10-0.66-7.5%$8.69$9.115$7.5820,885
$8.76-0.53-5.7%$9.39$9.939$8.7630,596
$9.29-0.60-6.1%$9.15$9.725$9.1534,615
$9.89+1.71+20.9%$9.01$10.00$8.5278,982
$8.18-0.66-7.5%$8.72$8.72$8.02521,689
$8.84+1.56+21.4%$7.87$8.89$7.0055,708
$7.28-0.62-7.8%$8.10$8.10$7.1934,943
$7.90-0.64-7.5%$8.33$8.70$7.9018,500
$8.54-0.23-2.6%$8.70$9.05$8.34112,400
$8.77+0.64+7.9%$8.51$8.97$8.2076,400
$8.13-0.495-5.7%$8.61$8.73$8.1361,900
$8.625+0.235+2.8%$8.46$8.625$8.0532,400
$8.39-0.55-6.2%$8.96$8.96$8.1319,800
$8.94+0.22+2.5%$8.84$9.39$8.539,600
$8.72-0.12-1.4%$9.01$9.14$8.2615,300
$8.84-0.46-4.9%$9.35$10.00$8.5528,600
$9.30-0.42-4.3%$9.58$10.05$8.8047,000
$9.72-0.09-0.9%$9.83$10.75$9.5550,700
$9.81+0.055+0.6%$9.99$10.98$9.6982,000
$9.755-0.305-3.0%$10.25$10.25$9.3071,500
$10.06+0.40+4.1%$9.90$10.10$9.56547,400
$9.66-0.39-3.9%$10.42$10.42$9.3286,400
$10.05+0.67+7.1%$9.236$10.10$8.5378,500
$9.38+0.22+2.4%$9.52$9.81$9.0718,700
$9.16-0.715-7.2%$9.63$10.13$9.1663,700
$9.875-0.245-2.4%$10.26$10.74$9.39126,400
$10.12-0.13-1.3%$11.00$11.00$9.7816,400
$10.25-0.79-7.2%$11.05$11.05$10.0027,600
$11.04-0.26-2.3%$11.43$11.61$10.6840,000
$11.30+0.42+3.9%$10.51$11.50$10.51134,100
$10.88+0.31+2.9%$10.63$11.07$10.07166,000
$10.57-0.39-3.6%$10.89$12.15$10.02131,100
$10.96-0.51-4.4%$11.32$12.04$10.75128,500
$11.47+0.63+5.8%$10.41$11.82$10.17108,600
$10.84+0.69+6.8%$10.00$11.40$9.6561,900
$10.15-0.22-2.1%$10.09$10.40$9.6046,500
$10.37-0.06-0.6%$10.44$10.50$9.44174,800
$10.43-0.27-2.5%$10.62$11.40$9.7581,400
$10.70+1.69+18.8%$8.93$11.08$8.80168,400
$9.01-0.09-1.0%$9.60$9.60$8.7554,000
$9.10+1.23+15.6%$8.10$9.96$7.95254,600
$7.87+0.40+5.4%$7.97$8.10$7.6930,400
$7.47-0.38-4.8%$8.00$8.06$7.35541,400
$7.85+0.06+0.8%$8.095$8.10$7.7011,000
$7.79-0.11-1.4%$8.10$8.10$7.6916,500

Splits

3 splits since 2015 · NASDAQ:AKTX · every price before a split is adjusted for it

DayRatioWhat
1-for-40Consolidation
1-for-20Consolidation
1-for-10Consolidation
Ticker
NASDAQ:AKTX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Akari Therapeutics PLC news

Akari Therapeutics PLC on 6ix

Sector
Health care
Industry
Biotechnology
News releases
6 in the last 12 months · 6 in all · newest Nov 12, 2026 · oldest 2025
Decks
32 decks · latest November 2026

Valuation

Price/book 0.9× against a median of 1.6×: 5th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$10.66M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
0.9×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.49

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Akari Therapeutics PLC · NASDAQ:AKTXUS$16.41MUS$10.66Mn/an/an/a0.9×n/a0.0×1.49
SynCore Biotechnology Co., Ltd. · TPEX:4192US$16.80MUS$12.38Mn/a15.6×n/a2.5×−178.5%0.0×n/a
Initiator Pharma A/S · OMXSTO:INITUS$16.74MUS$15.65Mn/an/an/a13.4×n/a1.1×n/a
Neurotech International Ltd. · ASX:NTIUS$16.63MUS$15.06Mn/an/an/a41.1×n/a0.0×n/a
Lipocine Inc. · NASDAQ:LPCNUS$16.39M−US$5.07Mn/a−1.4×n/a0.8×−249.2%0.0×1.18
MaaT Pharma · EURONEXT:MAATUS$16.11MUS$23.36Mn/a4.7×n/an/a−686.6%n/an/a
Elicera Therapeutics AB · OMXSTO:ELICUS$16.09MUS$10.40Mn/an/an/a2.9×n/a0.0×n/a
Pasithea Therapeutics Corp. · NASDAQ:KTTAUS$16.00M−US$25.22Mn/an/a−0.1×0.4×n/a0.0×0.97
Atossa Therapeutics, Inc. · NASDAQ:ATOSUS$15.92M−US$4.66Mn/an/an/a0.7×n/a0.0×0.87
Quoin Pharmaceuticals. Ltd · NASDAQ:QNRXUS$15.76M−US$17.43Mn/an/an/a0.6×n/a0.0×0.68
Celularity Inc. · NASDAQ:CELUUS$15.02MUS$50.46Mn/a2.7×n/an/a−117.3%n/a1.47
Median of the othersUS$16.10MUS$11.39M3.7×−0.1×1.6×−213.8%0.0×0.97

Forecasts

2 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
25.50 USD · Analysts' mean
EPS, year to Dec 2026
-9.05 · 1 analyst

Team and board

Officers

OfficerRole
Abizer GaslightwalaDirector, President and CEO
Kameel D. FaragInterim Chief Financial Officer
Satyajit MitraExecutive Director, Head of Oncology
Vatnak Vat-HoChief Business Officer

Board

DirectorRole
Hoyoung HuhChairman
Abizer GaslightwalaDirector, President and CEO
Ray PrudoDirector
Robert BazemoreDirector
Samir R. PatelDirector
Sandip I. PatelDirector
Satyajit MitraExecutive Director, Head of Oncology

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026 · After close+4.5%
Q2 2026Aug 13, 2026 · After close+7.7%
Q1 2026May 19, 2026 · After close−8.3%
Q3 2025Nov 13, 2025 · After close+1.7%
Q2 2025Aug 13, 2025 · After close−1.3%
Q1 2025Apr 15, 2025−1.2%
Q3 2024Dec 6, 2024−7.9%
Q2 2024Sep 30, 2024 · Before open+0.3%
Q1 2024May 15, 2024 · After close+1.4%
Q3 2023Oct 12, 2023 · Before open−2.8%
All 19 quarters
QuarterResultsShare move
Q2 2023Sep 29, 2023 · Before open−3.2%
Q1 2023May 1, 2023 · Before open+2.2%
Q4 2022Mar 30, 2023 · Before open−16.2%
Q3 2022Dec 30, 2022 · Before open+6.8%
Q2 2022Sep 27, 2022 · After close+7.7%
Q1 2022May 16, 2022 · Before open−2.7%
Quarter to Sep 30, 2021Dec 3, 2021 · Before open−2.2%
Q2 2021Sep 22, 2021 · After close−1.2%
Quarter to Mar 31, 2021Jun 29, 2021 · After close0.0%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck29 slidesNovember 2026
Investor Presentation (October 2026)Investor deck30 slidesOctober 2026
Investor Presentation (September 2026)Investor deck30 slidesSeptember 2026
Investor Presentation (August 2026)Investor deck30 slidesAugust 2026
Investor Presentation (June 2026)Investor deck27 slidesJune 2026
Investor Presentation (May 2026)Investor deck28 slidesMay 2026
Investor Presentation (February 2026)Investor deck24 slidesFebruary 2026
Investor Presentation (December 2025)Investor deck25 slidesDecember 2025
Investor Presentation (October 2025)Investor deck20 slidesOctober 2025
Investor Presentation (September 2025)Investor deck22 slidesSeptember 2025
All 32 decks
DeckKindSlidesDate
Investor Presentation (August 2025)Investor deck22 slidesAugust 2025
Investor Presentation (June 2025)Investor deck19 slidesJune 2025
Investor Presentation (April 2025)Investor deck29 slidesApril 2025
Investor Presentation (February 2025)Investor deck26 slidesFebruary 2025
Investor Presentation (January 2025)Investor deck26 slidesJan 13, 2025
Investor Presentation (October 2024)Investor deck40 slidesOct 29, 2024
Merger or Acquisition (March 2024)Merger or acquisition22 slidesMar 5, 2024
Investor Presentation (July 2023)Investor deck33 slidesJuly 2023
Investor Presentation (May 2023)Investor deck27 slidesMay 2023
Investor Presentation (February 2023)Investor deck24 slidesFebruary 2023
Investor Presentation (December 2022)Investor deck20 slidesDec 7, 2022
Investor Presentation (December 2021)Investor deck35 slidesDec 21, 2021
Investor Presentation (September 2021)Investor deck35 slidesSeptember 2021
Technical Presentation (May 2020)Technical16 slidesMay 1, 2020
Investor Presentation (September 2019)Investor deck37 slidesSep 10, 2019
Investor Presentation (May 2019)Investor deck25 slidesMay 29, 2019
Investor Presentation (October 2018)Investor deck25 slidesOct 1, 2018
Investor Presentation (August 2017)Investor deck33 slidesAugust 2017
Investor Presentation (July 2017)Investor deck33 slidesJuly 2017
Investor Presentation (January 2017)Investor deck26 slidesJan 9, 2017
Investor Presentation (December 2016)Investor deck21 slidesDec 6, 2016
Investor Presentation (July 2016)Investor deck21 slidesJul 12, 2016

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0000000000
Cost of revenue14.0K4.00K3.71K4.13K8.91K19.2K35.8K039.8K
Gross profit-14.0K-4.00K-3.71K-4.13K-8.91K-19.2K-35.8K0-39.8K
Research and development2.81M6.98M5.45M9.56M9.13M8.82M8.74M11.8M23.3M17.3M
Selling, general and administrative9.28M9.66M11.4M13.5M8.08M9.16M8.22M11.7M11.8M9.94M
Operating income-17.3M-21.6M-16.8M-23.1M-17.2M-18.0M-17.0M-20.8M-37.8M-27.2M
Depreciation and amortization014.0K4.00K4.00K4.13K8.91K19.2K35.8K42.4K39.9K
EBITDA-17.3M-21.6M-16.8M-23.1M-17.2M-18.0M-16.9M-20.7M-37.7M-27.2M
Interest expense100.0K244.0K05.34M210.1K205.0K267.0K82.0K00
Income before tax-18.3M-19.8M-10.0M-17.7K-17.4M-17.1M-16.8M-20.5M-35.4M-18.1M
Income tax-1.00M000000000
Net income-17.3M-19.8M-10.0M-17.7M-17.4M-17.1M-16.8M-20.5M-35.4M-18.1M
Earnings per share, basic0.000.000.000.000.00-0.01-0.01-0.01-0.03-0.02
Earnings per share, diluted0.000.000.000.000.00-0.01-0.01-0.01-0.03-0.02

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents5.20M03.85M13.3M9.36M14.1M5.73M5.45M28.1M34.1M
Short-term investments010.0M
Receivables201.0K2.95M3.51M4.54M10.4M
Inventory-2.49M-521.9K-1.03M-2.01M
Current assets5.46M2.95M4.34M13.8M11.6M14.6M6.44M7.45M28.8M45.6M
Property, plant and equipment0005.01K20.4K55.9K58.4K
Goodwill8.43M8.43M
Total assets47.9M50.6M4.36M13.8M11.6M14.6M6.48M8.03M29.1M45.9M
Accounts payable8.77M12.4M1.67M947.0K1.79M3.38M1.23M1.59M1.97M2.21M
Current liabilities12.4M19.9M4.58M12.0M6.09M5.22M5.46M4.92M11.8M11.7M
Total debt754.0K3.26M
Total liabilities19.6M28.3M4.58M12.0M6.09M5.22M6.47M4.92M11.9M11.8M
Shareholders' equity28.3M22.2M-229.0K1.79M5.55M9.38M7.60K4.37M22.2M34.1M
Shares outstanding90.5B53.2B13.2B7.44B4.76B3.85B2.25B312.0K1.53B1.18B

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-10.6M-12.6M-16.4M-21.5M-18.8M-17.0M-12.9M-22.8M-31.6M-24.6M
Capital spending00000000-36.9K-54.8K
Free cash flow-10.6M-12.6M-16.4M-21.5M-18.8M-17.0M-12.9M-22.8M-31.6M-24.7M
Cash from investing382.0K009.99M-10.1M
Cash from financing13.2M11.0M7.02M25.3M14.3M25.1M12.6M500.0K15.7M0
Share buybacks12.6M306.2K17.4M17.4M
Change in cash2.60M-1.19M-9.40M3.89M-4.69M8.32M-236.3K-22.3M-5.99M-34.8M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 19, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2026Big-stake noticeSEC
8-K · Current reportNov 12, 2026ResultsSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 12, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansOct 30, 2026Offer documentSEC
8-K · Current reportOct 30, 2026Meeting outcomeSEC
4 · Change in ownershipOct 16, 2026Insider tradeSEC
4 · Change in ownershipOct 16, 2026Insider tradeSEC
4 · Change in ownershipOct 16, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipOct 16, 2026Insider tradeSEC
4 · Change in ownershipOct 16, 2026Insider tradeSEC
4 · Change in ownershipOct 16, 2026Insider tradeSEC
4 · Change in ownershipOct 14, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 14, 2026Insider tradeSEC
DEF 14A · Proxy statementOct 1, 2026Meeting noticeSEC
4 · Change in ownershipOct 1, 2026Insider tradeSEC
8-K · Current reportOct 1, 2026Management or board changeSEC
4 · Change in ownershipAug 19, 2026Insider tradeSEC
8-K · Current reportAug 13, 2026ResultsSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeAug 12, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 7, 2026Big-stake noticeSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
4 · Change in ownershipJul 17, 2026Insider tradeSEC
EFFECT · Notice that a registration is effectiveJul 14, 2026Other filingsSEC
S-3/A · Registration statement, amendedJul 10, 2026Offer documentSEC
S-3/A · Registration statement, amendedJul 8, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveJul 8, 2026Other filingsSEC
8-K · Current reportJul 2, 2026Meeting outcomeSEC
S-3 · Registration statementJul 2, 2026Offer documentSEC
8-K · Current reportJun 26, 2026Material contractSEC
S-1/A · Registration statement, amendedJun 26, 2026Offer documentSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJun 8, 2026Big-stake noticeSEC
DEF 14A · Proxy statementJun 4, 2026Meeting noticeSEC
DJun 3, 2026Other filingsSEC
PRE 14A · Preliminary proxy statementMay 22, 2026Meeting noticeSEC
8-K · Current reportMay 22, 2026Material contractSEC
RW · Request to withdraw a registrationMay 21, 2026Other filingsSEC
10-Q · Quarterly reportMay 19, 2026Quarterly reportSEC
NT 10-Q · Late filing noticeMay 18, 2026Explanation requestSEC
S-1 · Registration statementMay 8, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveApr 16, 2026Other filingsSEC
POS AM · Amendment to an effective registrationApr 10, 2026Offer documentSEC
DRS · Draft registration statementApr 2, 2026Offer documentSEC
F-6/AMar 31, 2026Other filingsSEC
10-K · Annual reportMar 30, 2026Annual reportSEC
8-K · Current reportMar 17, 2026Current reportSEC
4 · Change in ownershipMar 16, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 4, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 4, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 4, 2026Big-stake noticeSEC
8-K · Current reportMar 2, 2026Meeting outcomeSEC
DEF 14A · Proxy statementFeb 3, 2026Meeting noticeSEC
EFFECT · Notice that a registration is effectiveJan 30, 2026Other filingsSEC
UPLOAD · Letter from the SECJan 27, 2026Other filingsSEC
CORRESP · Letter to the SECJan 27, 2026Other filingsSEC
S-1 · Registration statementJan 23, 2026Offer documentSEC
PRE 14A · Preliminary proxy statementJan 23, 2026Meeting noticeSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
8-K · Current reportDec 17, 2025Material contractSEC
424B5 · ProspectusDec 17, 2025Offer documentSEC
8-K · Current reportDec 16, 2025Meeting outcomeSEC
8-K · Current reportDec 8, 2025Current reportSEC
424B3 · ProspectusDec 5, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveDec 3, 2025Other filingsSEC
CORRESP · Letter to the SECDec 1, 2025Other filingsSEC
8-K · Current reportNov 26, 2025Current reportSEC
DEF 14A · Proxy statementNov 17, 2025Meeting noticeSEC
S-1 · Registration statementNov 17, 2025Offer documentSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
PRE 14A · Preliminary proxy statementNov 7, 2025Meeting noticeSEC
4 · Change in ownershipNov 4, 2025Insider tradeSEC
4 · Change in ownershipOct 24, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 24, 2025Insider tradeSEC
DOct 24, 2025Other filingsSEC
8-K · Current reportOct 23, 2025Management or board changeSEC
8-K · Current reportOct 16, 2025Material contractSEC
424B5 · ProspectusOct 16, 2025Offer documentSEC
8-K · Current reportOct 15, 2025Current reportSEC
8-K · Current reportSep 29, 2025Current reportSEC
8-K · Current reportSep 25, 2025Material contractSEC
S-1 · Registration statementAug 29, 2025Offer documentSEC
8-K · Current reportAug 29, 2025Material contractSEC
4 · Change in ownershipAug 29, 2025Insider tradeSEC
8-K · Current reportAug 21, 2025Material contractSEC
8-K · Current reportAug 19, 2025Current reportSEC
10-Q · Quarterly reportAug 13, 2025Quarterly reportSEC
EFFECT · Notice that a registration is effectiveAug 1, 2025Other filingsSEC
CORRESP · Letter to the SECJul 30, 2025Other filingsSEC
UPLOAD · Letter from the SECJul 30, 2025Other filingsSEC
S-8 · Registration statement for employee plansJul 29, 2025Offer documentSEC
S-3 · Registration statementJul 29, 2025Offer documentSEC
8-K · Current reportJul 1, 2025Management or board changeSEC
4 · Change in ownershipJun 25, 2025Insider tradeSEC
4 · Change in ownershipJun 24, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
ARS · Annual report to shareholdersJun 6, 2025Annual reportSEC
DEF 14A · Proxy statementJun 6, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementMay 23, 2025Meeting noticeSEC
8-K · Current reportMay 15, 2025ResultsSEC
EFFECT · Notice that a registration is effectiveMay 15, 2025Other filingsSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
424B3 · ProspectusMay 14, 2025Offer documentSEC
CORRESP · Letter to the SECMay 12, 2025Other filingsSEC
UPLOAD · Letter from the SECMay 9, 2025Other filingsSEC
S-3 · Registration statementMay 6, 2025Offer documentSEC
4 · Change in ownershipApr 29, 2025Insider tradeSEC
8-K · Current reportApr 16, 2025ResultsSEC
10-K · Annual reportApr 15, 2025Annual reportSEC
NT 10-K · Late filing noticeMar 31, 2025Explanation requestSEC
4 · Change in ownershipMar 24, 2025Insider tradeSEC
4 · Change in ownershipMar 24, 2025Insider tradeSEC
4 · Change in ownershipMar 24, 2025Insider tradeSEC
4 · Change in ownershipMar 24, 2025Insider tradeSEC
4 · Change in ownershipMar 24, 2025Insider tradeSEC
4 · Change in ownershipMar 24, 2025Insider tradeSEC
4 · Change in ownershipMar 24, 2025Insider tradeSEC
4 · Change in ownershipMar 24, 2025Insider tradeSEC
8-K · Current reportMar 20, 2025Management or board changeSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
8-K · Current reportMar 3, 2025Material contractSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
4/A · Change in ownership, amendedFeb 7, 2025Insider tradeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
8-K · Current reportJan 13, 2025Current reportSEC
4 · Change in ownershipJan 10, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipDec 30, 2024Insider tradeSEC
4 · Change in ownershipDec 30, 2024Insider tradeSEC
4 · Change in ownershipDec 27, 2024Insider tradeSEC
4 · Change in ownershipDec 27, 2024Insider tradeSEC
4 · Change in ownershipDec 26, 2024Insider tradeSEC
3 · Initial statement of ownershipDec 26, 2024Insider tradeSEC
4 · Change in ownershipDec 26, 2024Insider tradeSEC
4 · Change in ownershipDec 26, 2024Insider tradeSEC
3 · Initial statement of ownershipDec 20, 2024Insider tradeSEC
8-K · Current reportDec 18, 2024Management or board changeSEC
8-K · Current reportDec 16, 2024Management or board changeSEC
8-K · Current reportDec 12, 2024Management or board changeSEC
SC 13D/A · Big-stake notice, amendedDec 6, 2024Big-stake noticeSEC
4 · Change in ownershipDec 3, 2024Insider tradeSEC
4 · Change in ownershipDec 3, 2024Insider tradeSEC
3 · Initial statement of ownershipNov 22, 2024Insider tradeSEC
3 · Initial statement of ownershipNov 22, 2024Insider tradeSEC
3 · Initial statement of ownershipNov 22, 2024Insider tradeSEC
10-Q · Quarterly reportNov 19, 2024Quarterly reportSEC
4 · Change in ownershipNov 18, 2024Insider tradeSEC
NT 10-Q · Late filing noticeNov 15, 2024Explanation requestSEC
8-K · Current reportNov 14, 2024Acquisition or disposalSEC
8-K · Current reportNov 8, 2024Meeting outcomeSEC
4 · Change in ownershipNov 1, 2024Insider tradeSEC
425Oct 15, 2024Other filingsSEC
EFFECT · Notice that a registration is effectiveOct 15, 2024Other filingsSEC
424B3 · ProspectusOct 11, 2024Offer documentSEC
CORRESP · Letter to the SECOct 9, 2024Other filingsSEC
S-4/A · Registration statement, amendedOct 9, 2024Offer documentSEC
8-K · Current reportOct 4, 2024Current reportSEC
4 · Change in ownershipOct 2, 2024Insider tradeSEC
CORRESP · Letter to the SECSep 30, 2024Other filingsSEC
S-4/A · Registration statement, amendedSep 30, 2024Offer documentSEC
UPLOAD · Letter from the SECSep 26, 2024Other filingsSEC
4 · Change in ownershipSep 18, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 18, 2024Insider tradeSEC
8-K · Current reportSep 18, 2024Management or board changeSEC
424B5 · ProspectusSep 16, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveSep 16, 2024Other filingsSEC
S-4 · Registration statementSep 13, 2024Offer documentSEC
CORRESP · Letter to the SECSep 11, 2024Other filingsSEC
UPLOAD · Letter from the SECSep 11, 2024Other filingsSEC
S-3 · Registration statementSep 6, 2024Offer documentSEC
8-K · Current reportSep 6, 2024Current reportSEC
8-K/A · Current report, amendedAug 23, 2024Management or board changeSEC
10-Q · Quarterly reportAug 19, 2024Quarterly reportSEC
8-K · Current reportAug 19, 2024ResultsSEC
NT 10-Q · Late filing noticeAug 15, 2024Explanation requestSEC
4 · Change in ownershipJul 2, 2024Insider tradeSEC
4 · Change in ownershipJul 2, 2024Insider tradeSEC
4 · Change in ownershipJul 2, 2024Insider tradeSEC
4 · Change in ownershipJul 2, 2024Insider tradeSEC
4 · Change in ownershipJul 2, 2024Insider tradeSEC
8-K · Current reportJul 1, 2024Meeting outcomeSEC

This page holds 200 of 748 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Akari Therapeutics PLC’s releases

Common shares
2,285,165
Fully diluted
2,285,165

Fully diluted

LineShares
Common shares2,285,165

Share count over time

CountShares
Nov 22, 20262,285,165

Open Cap table

Shareholders

HolderSharesOf the companyValueAs of
Vestmark Advisory Solutions, Inc.37,688<0.01%US$350KSep 30, 2026
Jane Street23,242<0.01%US$216KSep 30, 2026
Citadel21,637<0.01%US$201KSep 30, 2026
Cresset Asset Management, LLC20,561<0.01%US$191KSep 30, 2026
Occidental Asset Management, LLC18,125<0.01%US$169KSep 30, 2026
MMCAP International Inc. SPC11,427<0.01%US$106KSep 30, 2026
Tower Research Capital LLC (TRC)385<0.01%US$3,581Sep 30, 2026
IFP Advisors, Inc181<0.01%US$1,683Sep 30, 2026
Nuveen86<0.01%US$836Sep 30, 2026
SBI Securities Co., Ltd.15<0.01%US$140Sep 30, 2026
All 12 holders
HolderSharesOf the companyValueAs of
Caitong International Asset Management Co., Ltd10<0.01%US$93Sep 30, 2026
Northwestern Mutual Wealth Management Co7<0.01%US$65Sep 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Wendy DiCicco
Other companies: EyePoint, Inc. (Board Member · Since at least Jul 15, 2019); SWK Holdings Corp (Director · Feb 15, 2022 – Dec 30, 2022 · Past); CannaPharmaRx Inc. (Director · Feb 27, 2015 – Feb 27, 2015 · Past); Coherent Corp. (Director · Aug 17, 2013 – Apr 28, 2017 · Past)
Interim CFO · Jan 1, 2024 – May 1, 2024 · Past
James R. Neal
Other companies: Processa Pharmaceuticals, Inc. (Director · Since at least Jul 19, 2022); Monterey Bio Acquisition Corp (Director · Sep 30, 2021 – Sep 30, 2021 · Past); Palisade Bio, Inc. (Director · Apr 27, 2021 – Feb 9, 2024 · Past)
Director · Since at least Nov 14, 2024
Michael Grissinger
Other companies: Lipocine Inc. (Director · Since at least Aug 3, 2026); Aprea Therapeutics, Inc. (Director · Since at least May 16, 2022); Adicet Bio, Inc. (Director · Since at least Nov 5, 2018)
Director · Jan 1, 2024 – Jun 28, 2024 · Past
Rachelle Jacques
Other companies: uniQure N.V. (Director · Since at least Oct 21, 2021); Corbus Pharmaceuticals Holdings, Inc. (Director · Since at least Jun 17, 2021); Viela Bio Inc (Director · Mar 15, 2021 – Mar 15, 2021 · Past)
Chief Executive Officer, Director · Jan 1, 2024 – Apr 26, 2024 · Past
Robert Bazemore
Other companies: Nuvation Bio Inc. (Director · Since at least Sep 3, 2024); Ardelyx, Inc. (Director · Since at least Jun 14, 2024)
Director · Since at least Sep 17, 2024
Donald A. Williams
Other companies: Palisade Bio, Inc. (Director · Since at least Jun 10, 2026)
Director · Jan 1, 2024 – Jun 28, 2024 · Past
Hoyoung Huh
Other companies: Pliant Therapeutics, Inc. (Director · Since at least Jun 16, 2022)
Chairman · Since at least Nov 14, 2024
Mohamed Wa'el Ahmed Hashad
Other companies: Longeveron Inc. (Chief Executive Officer · Since at least Mar 1, 2023)
Director · Jan 1, 2024 – Jun 28, 2024 · Past
Torsten Hombeck
Other companies: Aspira Women's Health Inc. (Chief Financial Officer · Jun 15, 2023 – May 13, 2024 · Past)
CFO · Dec 16, 2024 – Mar 20, 2025 · Past
Abizer GaslightwalaDirector, President and CEO · Since at least Oct 16, 2026
All 20 people
PersonSeat
Amos EiranDirector · Jan 1, 2015 – Jan 1, 2015 · Past
James HillDirector · Sep 18, 2015 – Jun 29, 2016 · Past
Kameel D. FaragInterim Chief Financial Officer · Since at least Nov 5, 2026
Pablo JimenezChief Medical Officer · Jan 1, 2015 – Jan 1, 2015 · Past
Raymond Prudo-ChleboszDirector · Since at least Dec 16, 2025
Ray PrudoDirector · Since at least Nov 5, 2026
Samir R. PatelDirector · Since at least Dec 16, 2025
Sandip I. PatelDirector · Since at least Oct 16, 2026
Satyajit MitraExecutive Director, Head of Oncology · Since at least Oct 30, 2026
Vatnak Vat-HoChief Business Officer · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Akari Therapeutics PLC.